FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer
Evidence for efficacy is based on the results from the FRESCO-2 and FRESCO studies
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
EMA Recommends Granting a Conditional Marketing Authorisation for Adagrasib Following a Re-Examination Procedure
It is intended for the treatment of adults with advanced NSCLC with KRAS G12C mutation and disease progression after at least one prior systemic therapy
Adjuvant Atezolizumab Plus Bevacizumab Improves RFS Among Patients at High Risk of HCC Recurrence Following Curative-Intent Resection or Ablation
Findings from the IMbrave050 study
Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab
A new method developed to measure the antibody levels against PD-1
Adding Durvalumab to First-Line Platinum-Based Chemotherapy Followed by Maintenance Durvalumab With Or Without Olaparib Improves PFS for Patients with Advanced Or Recurrent Endometrial Cancer
Findings from the DUO-E study
FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma
Evidence for efficacy is based on the results from the JUPITER-02 and POLARIS-02 studies
Regional Node Radiotherapy Significantly Reduced Breast Cancer Mortality and All-Cause Mortality in Newer but Not in Older Studies
Findings from an individual patient data meta-analysis performed by the Early Breast Cancer Trialists’ Collaborative Group could reflect radiotherapy improvements
FDA Approves Ivosidenib for Myelodysplastic Syndromes
It also approved a companion diagnostic device to select patients for the treatment with ivosidenib
FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer
Evidence for efficacy is based on the results from the KEYNOTE-966 study
Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for Whom the Standard Regimen is Unsuitable
Findings from the CABASTY study
Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Results in Greater EFS and pCR in Patients with Resectable NSCLC Than Neoadjuvant Chemotherapy Alone
Findings from the AEGEAN study
Erdafitinib Prolongs Survival in Patients with Metastatic Urothelial Carcinoma and FGFR Alterations After Previous Anti–PD1(-L1) Treatment
Findings from the THOR Cohort 1 study